A continued and robust federal investment in research funding will improve outcomes for pancreatic cancer patients diagnosed today and in the future.

WHY IS THIS URGENT?

• Pancreatic cancer is one of the deadliest major cancers and has the lowest five-year survival rate at just 13%.1
• Pancreatic cancer is the 3rd leading cause of cancer-related deaths in the U.S., and it’s projected to move to 2nd by 2030.1, 2
• There is no standard early detection test for pancreatic cancer, and few effective treatments are available.

WHY NIH & NCI?

National Institutes of Health (NIH) and National Cancer Institute (NCI) funding supports the foundational science necessary to accelerate early detection strategies and more effective treatments. The NIH is the largest source of funding for pancreatic cancer research.

WHY INVEST?

Because of the incredible promise of cancer research, NCI receives more research grant applications than any other Institute or Center at NIH, by far. But the scientific demand has far outpaced NCI’s budget, meaning that 6 out of every 7 proposals are going unfunded.5

The only way to meet this demand is by boosting funding for NCI.

To ensure pancreatic cancer patients have more treatment options and better outcomes today and in the future, Congress must increase the investment at NIH and NCI in FY25.